MAIA Biotechnology Inc Dossier - Source-backed chat

MAIA Biotechnology Inc

MAIANYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.50

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.17Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $72.2M

Enterprise Value $72.2M

Shares Outstanding 56.2M diluted

Next Earnings Date13 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

MAIA Biotechnology is a clinical-stage biopharmaceutical company advancing ateganosine (THIO), a potential first-in-class cancer telomere-targeting agent. The company's investment thesis is anchored on the clinical momentum of its lead asset in non-small cell lung cancer (NSCLC). MAIA has successfully transitioned into a pivotal Phase 3 trial (THIO-104) for third-line (3L) advanced NSCLC, supported by a robust $33 million capital raise in early 2026 that secures its near-term operational runway. Efficacy data from its Phase 2 THIO-101 trial demonstrated a median overall survival of 17.8 months compared to the historical standard-of-care chemotherapy benchmark of 5.8 months, representing a highly compelling therapeutic profile in a heavily pre-treated patient population with significant unmet medical needs.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.27

Mean target$12.14

High · most bullish analyst$14.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.9915%

The bear case is defined by clinical trial delays, slower-than-expected patient recruitment in the Phase 3 trial, or safety/efficacy signals that do not match the strong Phase 2 results. Additionally, as a pre-revenue biotech, any failure to secure non-dilutive funding or strategic partnerships would force further dilutive equity raises, depressing the share price.

Base CaseCentral scenario

$12.1460%

Matches the consensus mean

The base case projects steady progress in the Phase 3 THIO-104 trial with interim survival analysis on track for 2027. The Phase 2 THIO-101 expansion trial continues to enroll patients across US, European, and Asian sites, yielding positive interim Overall Response Rate (ORR) data. The $33 million capital raise successfully funds operations through the completion of the Phase 3 trial, with the stock moving toward consensus analyst targets as clinical milestones are achieved.

Bull CaseUpside scenario

$14.0025%

The bull case assumes rapid enrollment in the pivotal Phase 3 THIO-104 trial, meeting the target of 100 patients by year-end 2026. Efficacy remains consistent with Phase 2 results (median overall survival of 17.8 months), leading to an accelerated FDA approval pathway. Strong clinical data triggers a lucrative co-development or licensing partnership with a major pharmaceutical company, significantly boosting valuation and providing non-dilutive funding.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-in-class telomere-targeting mechanism of action with dual-action telomere damage and immune system activation.
Compelling Phase 2 clinical efficacy showing median overall survival of 17.8 months vs. 5.8 months for standard chemotherapy in 3L NSCLC.
FDA Fast Track designation for lead asset ateganosine (THIO) in 3L NSCLC, facilitating accelerated regulatory pathways.
Strong balance sheet following a $33 million capital raise in early 2026, fully funding the pivotal Phase 3 trial through completion.
Active insider alignment, highlighted by recent open-market stock purchases by the CEO and directors.

Key Investment Risks

Clinical development risk: Efficacy or safety profile may degrade in the larger, randomized Phase 3 trial compared to Phase 2.
Regulatory risk: Potential delays or failure to obtain FDA accelerated or full commercial approvals.
Dilution risk: As a pre-revenue clinical-stage company, MAIA remains dependent on capital markets and may require future dilutive equity offerings.
Enrollment risk: Delays in activating clinical sites or recruiting the target patient population for the THIO-104 and THIO-101 trials.

Thesis Invalidation Triggers

Failure of the Phase 3 THIO-104 trial to meet its primary endpoint of median Overall Survival (OS).
Severe adverse safety events leading to an FDA clinical hold on ateganosine (THIO) trials.
Inability to meet patient enrollment targets for the Phase 3 trial by the end of 2026, significantly delaying the 2027 interim analysis.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.